Table 1 Clinical trial of targeted PD-1 inhibitor combined with RT/CRT for ESCC being recruited
Tumor type | Study cohort | Control cohort I | Phase | Primary endpoints | Registration |
|---|---|---|---|---|---|
ESCC/EAC/GEJC | Pembrolizumab + FP or FOLFOX therapy + RT | Placebo + FP or FOLFOX therapy + RT | III | EFS, OS | NCT04210115 |
Locally advanced ESCC | Sintilimab + cisplatin + paclitaxel + RT | Cisplatin + paclitaxel + RT | III | OS | NCT05357846 |
Locally advanced resectable ESCC | Tislelizumab + carboplatin + paclitaxel + RT | Carboplatin + paclitaxel + RT | III/II | pCR, OS | NCT04973306 |
Locally advanced ESCC | Tislelizumab + cisplatin + paclitaxel + RT + 12 additional cycles of tislelizumab | Tislelizumab + cisplatin + paclitaxel + RT | II | PFS | NCT05520619 |
Resectable thoracic ESCC | PD-1 inhibitor + cisplatin + albumin-bound paclitaxel | Cisplatin + albumin-bound paclitaxel + RT | II | pCR | NCT05007145 |
Resectable ESCC | Pembrolizumab + carboplatin + paclitaxel + RT | - | II | pCR | NCT04435197 |
Oligometastatic ESCC | Tislelizumab + Triprizumab + cisplatin + albumin-bound paclitaxel + RT | - | II | LCR | NCT04821765 |
Locally advanced resectable ESCC | Toripalimab + carboplatin + paclitaxel + RT | - | II | pCR | NCT05424432 |
Locally advanced ESCC | Toripalimab + carboplatin + paclitaxel liposome + RT | - | II | pCR | NCT04644250 |
Metastatic ESCC | Standard chemotherapy + PD-1 inhibitor + RT + capecitabine | Standard chemotherapy + PD-1 inhibitor | II | 1-year PFS | NCT05512520 |
Advanced ESCC | Tislelizumab + cisplatin + albumin-bound paclitaxel + RT | - | II | MPR, pCR | NCT05323890 |